Sequana Medical announces H1 2022 results and provides business update

  • alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022
  • DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study in H1 2023
  • Total liquidity position of €23.8 million and cash runway into Q3 2023

Conference call with live webcast presentation today at 03:00 pm CET / 09:00 am ET

Ghent, Belgium – 8 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH